A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-03

Study Completion Date

2016-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A real-world, point-of-care, randomized, parallel group, open, 6-month clinical study to evaluate if the provision of a digital disease management tool improves glycaemic control in participants with type 2 diabetes mellitus (T2DM), as measured by change from baseline to End of Study (Month 6) in glycosylated haemoglobin (HbA1c) levels. Clinical assessments for this study will be conducted as part of normal, standard care. The main objective of this study is to evaluate the effect of adding this tool to participants' current standard care for T2DM on glycaemic control, other variables of importance in T2DM (eg, weight, blood pressure, and lipid levels), and participant-reported outcomes (PROs), such as satisfaction with treatment and adherence to their antihyperglycaemic treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. This is an open design study, in which the patients will be aware of the guidance they are receiving via the provided support tool. Study duration of 6 months has been chosen, as a reasonable amount of time to evaluate the tool. Glycaemic control is considered to be the goal of a T2DM disease management plan. In T2DM, long-term goals may not be achieved because participants fail to adhere to their management plan after an initial period of compliance. The study will compare the group receiving the digital disease management tool added to standard care for T2DM to a concurrent control group receiving standard care. Standard of Care cohort: Participants will have standard care with no access to the digital disease management tool. Clinical assessments for this study will be conducted as part of normal, standard care. Participants in the Standard of Care + digital disease management cohort will be taken through their standard T2DM management plan by their HCP (Health Care Provider) and trained in the use of the digital disease management tool. All participants will complete the PRO assessments. This study also aims at helping the health care practitioners and managed care providers to make evidence-based decisions about how to improve patient self-management of their diabetes. Participants diagnosed with T2DM and on one or more non-insulin antihyperglycaemic medications will be offered participation in the study at their point of care. Participants in the Standard of Care cohort will be taken through their T2DM management plan with their HCP per standard care. It is not anticipated that the use of this patient tool will be associated with any increase in risk to participating patients. The study will be performed in accordance with ethical principles that are consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP), applicable regulatory requirements, and the AZ policy of bioethics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type II Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Digital disease management tool Type 2 diabetes mellitus/ T2DM HbA1c Standard care PRO questionnaires Smart phone/ personal computer with internet access

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care + digital disease management cohort

Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.

Use of digital disease management tool in participants with T2DM

Intervention Type OTHER

The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.

Standard of Care cohort

Participants will have standard care with no access to the digital disease management tool.

Use of digital disease management tool in participants with T2DM

Intervention Type OTHER

The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Use of digital disease management tool in participants with T2DM

The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For inclusion in the study participants must fulfill the following criteria:

* Provision of written informed consent prior to any study-specific procedures.
* Female or male aged ≥18 years at time of consent.
* Diagnosed with T2DM.
* Treatment with one or more non-insulin antihyperglycaemic medication(s) for at least 6 months prior to enrolment
* Own/have access to a smart phone with internet access and have access to the internet via a tablet or personal computer at least once a day. At the HCP's discretion, a patient may be without access to their smart phone service, data connection, and internet access for a period of time that should be ≤2 consecutive weeks
* HbA1c levels ≥8.0% and ≤11.0% within the last 6 months. If more than 1 value is available during the 6-month time period, all values must be within this range
* Body mass index (BMI) ≥25 and ≤55 kg/m2 within the last 3 months
* Ability to communicate in English
* Judged by their HCP to have suitable hearing, vision, manual dexterity, ability to understand instructions, and ability to use and understand smart phone and internet applications
* Negative pregnancy test (urine or serum) for female patients of childbearing potential

Exclusion Criteria

* Pregnancy
* Insulin use at baseline
* Current use of a smart phone- or web portal-based tool to help with management of T2DM
* History of type I diabetes or ketoacidosis
* Currently taking a weight loss medication
* Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff and affiliates at the study site)
* Previous enrolment in the present study
* Participation in a clinical study with an investigational product or a disease state management program during the last 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Role: PRINCIPAL_INVESTIGATOR

Llanderyn Health Centre

Review additional registry numbers or institutional identifiers associated with this trial.

D1841C00002

Identifier Type: -

Identifier Source: org_study_id

A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Standard of Care + digital disease management cohort

Use of digital disease management tool in participants with T2DM

Standard of Care cohort

Use of digital disease management tool in participants with T2DM

Interventions

Use of digital disease management tool in participants with T2DM

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Parexel

AstraZeneca

Responsible Party

Principal Investigators

Manesh Saxena

Deepak Bhatnagar

Aled Roberts

Melanie Davies

See Kwok

Keith Richardson

Deborah Wake

Ruth Leese

Neela Chatakondu

Tom Hoyland

Allan Copland

Calum MacKenzie

Simon Barrett

John Shewring

Locations

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Countries

Related Links

Other Identifiers

D1841C00002